MetaCap

Agios Pharmaceuticals (AGIO) vs Korsana Biosciences (KRSA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Korsana Biosciences (KRSA) has outperformed Agios Pharmaceuticals (AGIO) over the past year, gaining 262.5% versus a gain of 9.4%. Over five years, AGIO leads with a -24.3% price change compared with -89.0% for KRSA. Korsana Biosciences is the larger company by market cap ($1.71 billion vs $1.65 billion), about 1.0 times the size, while Agios Pharmaceuticals is growing revenue faster (+48.0% vs +3.7%).

Korsana Biosciences converts more of its revenue into profit, with a net margin of -170.1% versus -764.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGIO+9.35%KRSA+262.55%
+349%+152%-45%
Nov 21, 20251 yearNov 20, 2026
AGIO-27.79%KRSA-88.44%
+69%-18%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGIO versus KRSA key metrics
MetricAGIOKRSA
Share price$27.60$37.56
Market cap$1.65B$1.71B
1-day change-4.03%+5.95%
YTD return+1.40%+322.50%
1-year return+9.35%+262.55%
5-year return-24.28%-89.05%
EPS (TTM)$-6.31$-16.14
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$54.03M$2.07M
Revenue growth (YoY)+48.03%+3.70%
Net income (latest FY)$-412.78M$-3.53M
Gross margin88.26%—
Operating margin-873.87%-239.78%
Net margin-764.01%-170.11%
52-week high$44.09$59.36
52-week low$24.16$7.19
Distance from 52-week high-37.40%-36.73%
Analyst consensusbuystrong_buy
Avg. price target upside+67.07%+17.15%
Average volume1.06M119.71K
Shares outstanding59.81M45.54M
Employees53919
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KRSA has outperformed AGIO by 253.2 percentage points over the past year.
  • Korsana Biosciences is more profitable, keeping -170.1 cents of every revenue dollar as net income versus -764.0 cents for Agios Pharmaceuticals.
  • Agios Pharmaceuticals grew revenue faster in its latest fiscal year (+48.03% vs +3.70%).

About Agios Pharmaceuticals

AGIO stock →

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.

Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees

About Korsana Biosciences

KRSA stock →

Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

AGIO vs KRSA FAQ

Which is bigger, Agios Pharmaceuticals or Korsana Biosciences?

Korsana Biosciences (KRSA) is larger, with a market capitalization of $1.71B compared with $1.65B for Agios Pharmaceuticals (AGIO).

Which stock has performed better over the past year, AGIO or KRSA?

KRSA returned +262.55% over the past 12 months, compared with +9.35% for AGIO (price return, excluding dividends). Past performance does not predict future results.

Are Agios Pharmaceuticals and Korsana Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons